Biopharmaceutical company Nxera Pharma has launched a broad new pipeline strategically focused on advancing therapies for obesity and associated metabolic disorders. 

Independent to the productive drug discovery collaborations with Pfizer and Eli Lilly, Nxera has established, expanded and accelerated drug discovery efforts of its own proprietary pipeline across a broad range of validated GPCR targets in these major disorders. 

Chris Cargill, President and CEO of Nxera, commented: “Nxera scientists were among the pioneers in elucidating the structure of the GLP-1 receptor and other key receptors being targeted, giving us a clear advantage in developing potentially best-in-class next generation drug candidates. For the past 12 months, Nxera scientists have been advancing a broad metabolic disease pipeline to capitalise independently on our differentiated science.  

“Today, we reveal the addition of these programmes to our discovery portfolio, and are confident in achieving significant progress over the mid-term, delivering clear value for shareholders and patients in the rapidly expanding obesity market, projected to exceed $100 billion annually in global sales.” 

Central to Nxera’s pipeline is its oral small molecule GLP-1 agonist programme, focussed on differentiated chemistry, which is distinct, independent and developed separately from Pfizer’s PF-06954522. 

Complementing this programme, Nxera is simultaneously developing an additional six established GPCR-targeted programs focused on obesity and chronic weight management. These include three small molecule agonist programmes (GIP, Apelin, Amylin), one small molecule antagonist programme (GIP), and two long-acting programmes (targets undisclosed). 

Pfizer has discontinued development of its Phase I candidate PF-06954522, a separate small molecule GLP-1 agonist, which was discovered under a strategic drug discovery collaboration with Nxera, due to a portfolio decision. Nxera has revealed its intention to enter discussions with Pfizer regarding potential opportunities to advance GLP-1 molecules discovered by Pfizer under the collaboration.

Diana Turner, Senior Digital Content Editor, DDW